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Abstract
Background: Hepatocellular Carcinoma (HCC) is a common malignancy occurring globally but with a dismal
prognosis. Des-gamma-carboxyprothrombin (DCP) has been reported to be more sensitive and specific than Alpha-
fetoprotein (AFP) in the diagnosis of HCC among the White population. Its efficacy among the Black population is
yet to be established. The aim of this study therefore, was to determine the relative sensitivity and specificity of
des-gamma-carboxyprothrombin and alpha-fetoprotein in the diagnosis of hepatocellular carcinoma in a cohort of
Nigerian patients presenting at a single referral centre.
Methods: Cross-sectional case–control study was carried out using 62 HCC patients and 57 controls with benign
liver diseases including chronic hepatitis and compensated liver cirrhosis. Both DCP and AFP were tested using
enzyme immunoassay methods.
Results: Sixty-nine percent of the HCC patients presented with tumour sizes >5 cm while 31 % presented with
tumour sizes 3-5 cm. No patient presented with tumour sizes <3 cm. The sensitivity and specificity of DCP were
96.8 % and 98.3 % respectively, based on a Receiver operating characteristic (ROC) curve - derived optimum cut-off
level of >140mAU/ml. Similarly, the sensitivity and specificity of AFP were 62.9 % and 93.3 % at an ROC - derived
optimum cut-off level of 18mAU/ml. The area under the receiver operating characteristic curve (AUROC) for DCP
was 0.99 and was significantly larger than that of AFP which was 0.85 (p < 0.001).
Conclusion: In conclusion, the utility of DCP for the diagnosis of HCC among Nigerian patients was higher than
that of AFP for large tumours with diameter ≥3 cm.
Background
Hepatocellular carcinoma is the fifth most common ma-
lignancy and the third most common cause of cancer-
related deaths world-wide [1]. It is a disease with a
dismal prognosis [2]. The poor outcome is related to late
detection with more than two thirds diagnosed at the
advanced stages [3]. To achieve early diagnosis, attempts
have been made at discovering tumour markers. While
alpha-fetoprotein (AFP) is the most widely used tumour
marker for hepatocellular carcinoma (HCC) surveillance,
experience with des-gamma-carboxyprothrombin (DCP)
is limited.
Des-gamma-carboxyprothrombin is an abnormal pro-
thrombin released into the blood in the absence of
vitamin K or the presence of vitamin K antagonists such
as warfarin and is specific to hepatocellular carcinoma
[4]. The accuracy of DCP is reduced in prolonged ob-
structive jaundice, vitamin K deficiency as may occur in
severe malnutrition, or the use of vitamin K antagonists
such as warfarin [4–7]. It is formed as a result of a de-
fect in post- translational carboxylation of ten glutamic
acid residues at the N-terminal end of the prothrombin
molecule in malignant cells [8]. It was first detected in
the serum of patients with HCC in 1984 by Liebman et
al [4]. Thereafter, there have been series of studies com-
paring the sensitivity and specificity of AFP and DCP in
an attempt to aid early diagnosis. Many of the studies
have shown DCP to be more sensitive than AFP [9–12].
Some have reported AFP to be more sensitive than DCP
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However, further research clarified the discrepancies
by showing that the sensitivity of DCP and AFP vary ac-
cording to tumour sizes. It was found that AFP is more
sensitive for the diagnosis of small size tumours (<3 cm)
while DCP is more sensitive for larger size tumours
(>3 cm) [11, 15–20]. DCP was also found to be the most
useful predisposing clinical parameter for the develop-
ment of portal vein invasion [21].
Most of the studies on DCP have been carried out in
the White population, especially in Japan. Few studies
have used the Black population. In one of such studies
using the Black population, DCP values were found to
be significantly higher in cirrhotics and in White pa-
tients than in Black patients in America which may indi-
cate a higher sensitivity among Black individuals while
the converse may be true for AFP [12]. A study compar-
ing DCP and AFP as markers of HCC in South African
Black patients showed that the sensitivity and specificity
of DCP were less than those of AFP [13]. To date, there
is no report known to the authors regarding the use of
DCP in the diagnosis of HCC in Nigeria. The purpose of
this study was therefore to compare the sensitivity and
specificity of AFP and DCP among Nigerian patients
with HCC presenting at the Obafemi Awolowo Univer-




This was a cross-sectional case–control study. Patients
were drawn from referrals to the Liver Unit at the Oba-
femi Awolowo University Teaching Hospitals Complex,
Ile-Ife, from April 2011 to March 2012. Sixty-two con-
secutive patients presenting with untreated primary he-
patocellular carcinoma diagnosed using the European
Association for the Study of Liver Diseases (EASL) and
American Association for the Study of Liver Diseases
(AASLD) criteria were enrolled [22, 23]. The controls
were 57 patients with benign hepatic diseases which
comprised of 34 patients with chronic Hepatitis B infec-
tion, one patient with chronic Hepatitis C infection, 21
patients with compensated cirrhosis of the liver, and one
patient with Non-alcoholic Fatty Liver Disease . The pa-
tients were divided into two broad groups: HCC and
non-HCC groups. Ethical clearance was obtained from
the hospital ethical committee (Obafemi Awolowo Uni-
versity Teaching Hospital Complex, Ethics and Research
Committee clearance number: IRB/IEC/0004553) and
informed consent was obtained from all the patients be-
fore enrolling them for the study.
A full history and detailed clinical examination was
done on all the patients. Laboratory tests carried out in-
cluded Hepatitis B surface antigen and Hepatitis C anti-
body tests. Liver function tests including prothrombin
time were done by conventional methods. All the cases
and controls were subjected to abdominal ultrasound
while CT scan was restricted to those shown on ultra-
sound to have focal lesions in the liver. HCC diameter
was measured by ultrasound and/or CT scan. Patients
with a history of the use of warfarin or other dicoumar-
ols or total Bilirubin level above 20 mg/dl (340 μmol/l)
were excluded from the study. All the patients used for
this study were native Nigerians.
Five millilitres of venous blood was collected from all
the patients and sera stored at −20 °C until they were
analyzed for the tumour markers. The analysis for both
tumour markers (DCP and AFP) was carried out at a na-
tional research institute: Nigerian Institute for Medical
Research, Lagos, Nigeria.
AFP assay
AFP was tested using commercially available immuno-
enzymometric assay kit manufactured by INTECO Diag-
nostics, UK Ltd., London. The test was carried out as per
manufacturer’s instructions. The upper limit of normal for
the kits as given by the manufacturer was 10 IU/ml.
DCP assay
The DCP values were obtained using “Haicatch PIVKA-
II” enzyme Immunoassay test kit (Sanko Junyaku co.
Ltd., Tokyo, Japan). The tests were carried out as per the
manufacturer’s instructions. Briefly, the test involves
using anti-DCP monoclonal antibody coated on the
inner surface of the micro cup. DCP in the sample is
captured and allowed to react with enzyme-labelled anti-
human prothrombin antibody. When substrate solution
is added to the reaction product, the enzyme reaction
develops colour. DCP concentration is determined from
the absorbance of the coloured solution. The assay range
of the kit was 10–2000 mAU/ml. The upper limit of nor-
mal for the kit was given as 40mAU/ml by the
manufacturer.
Tumour- size determination
HCC diameter was measured by ultrasound and/or CT
scan and the longest axis was defined as the diameter of
the tumour. When HCC tumours were multiple, the lar-
gest was measured, and taken as a representative HCC
diameter. Based on previously published literature [15,





Data generated from the study was entered into Micro-
soft Excel and then transferred to STATA 10 software
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(Statacorp, Texas, USA) for data management and ana-
lysis. The baseline socio-demographic and clinical char-
acteristics were reported as mean ± standard deviation
computed for normally distributed continuous variables,
and median and their corresponding inter-quartile range
for non-normal continuous variables.
A comparison of the socio-demographic and clinical
characteristics of individuals with or without hepatocel-
lular carcinoma was performed. The student t-test was
employed to compare the normally continuous variables
by HCC status and the Wilcoxon rank sum test
employed to compare the non-normal continuous vari-
ables. The Pearson’s chi-square was used to find a differ-
ence in the proportions of the categorical variables
between the two groups. 2x2contingency tables were
employed to calculate the sensitivity and specificity of
both tests in detecting HCC. Receiver operating charac-
teristic (ROC) curves for both tests were drawn and
comparison of the area under the curves (AUROC) for
both tests done to establish which test is a better tumour
marker for HCC in Nigerians.
In patients with HCC, correlations between AFP and
DCP values and various patient characteristics were ex-
amined. Non-parametric Spearman rank correlation
(international normalised ratio, age, aspartate transamin-
ase (AST), alanine transaminase (ALT), albumin and
total bilirubin) was utilized to find the linear relationship
between DCP and AFP and other continuous variables
listed within the bracket. Significant correlation between
two variables was defined at a Spearman rank correl-
ation coefficient of 0.4 or higher and a 2-sided P- value
of less than 0.05.
Results
Patients characteristics
A total of 119 patients were enrolled in this study, con-
sisting of 62 patients with primary HCC and 57 controls.
All the patients used for this study were native Nigerians
and all were treatment naive before recruitment into the
study.
The baseline demographic and clinical characteristics
of both the cases and controls are shown in Table 1.
There were 48 males and 14 females among the cases
(ratio 3.4:1), while the controls had 38 males and 19 fe-
males (ratio 2:1). There was no significant difference in
the sex ratio of patients and controls (p = 0.19). The
mean age of the HCC patients was 46.3 (±15.6) years,
while that of the controls was 43.2(±12.2) years. There
was no significant difference in the mean ages of pa-
tients and controls (p = 0.05). The peak age incidence of
HCC was in the 35–55 years age- range (table 1). Hepa-
titis B infection was the most important etiologic factor
among the HCC cases (66.1 %) and non- HCC controls
(73.7 %).
Baseline data for AFP and DCP
Table 2 shows the baseline data for AFP and DCP re-
corded in mean ± standard deviation. It could be seen
from the table, that the serum levels of AFP and DCP
were significantly higher in the HCC patients than in the
non-HCC controls (p < 0.001). The normal values for the
DCP kits as given by the manufacturers were 0-40mAU/
ml while the normal values for the AFP kits were given
as 0–10 IU/ml. The median and the corresponding
inter-quartile ranges for AFP were 39(8–245) IU/ml for
HCC cases and 4.8(3–7) IU/ml for non-HCC controls
respectively (Fig. 1). For DCP, the median and the inter-
quartile ranges were 2000(2000–2000) mAU/ml for
HCC cases and 58 (40–72) mAU/ml for non-HCC con-
trols respectively (Fig. 2).
Optimal cut-off values for DCP and AFP in differentiating
HCC from benign lvier diseases
To determine the optimal cut-off value that balances
sensitivity and specificity, the ROC curves were plotted
for DCP and AFP (Fig. 3). From the ROC curves for
DCP, the optimal cut-off value for DCP in differentiating
HCC from benign liver diseases stood at 140mAU/ml.
Based on this ROC-defined cut-off level, the sensitivity
and specificity of DCP were 96.8 and 98.3 % respectively.
The AUROC for DCP in the diagnosis of HCC was 0.99
(95 % CI = 0.97-1.00).
Table 1 Demographic and clinical characteristics of hcc cases
and non-hcc controls
Median (Inter-quartile range) or N (%) *p-value
Variables HCC (n = 62) Non-HCC (n = 57)
Age (years) 49.5(35–55) 36(32–51) p = 0.05
Gender M:F 48:14 38:19 p = 0.19
AST (u/L) 89(68–112) 12(7–23) p < 0.001
ALT (u/L) 36(22–54) 8(5–16) p < 0.001
Total Bilirubin (μmol/l) 60.3(28–144) 18(11.1-29) p < 0.001
Albumin (g/l) 30(26–35) 36(34–39) p < 0.001
INR 1.19(1–1.4) 1.1(1–1.2) p = 0.22
Positive for HBsAg 41(66.1 %) 42(73.7 %) p = 0.52
Positive for Anti-HCV 0 %) 1(1.8 %) p = 0.30
*P value <0.05 is deemed significant
AST aspartate transaminase, HBsAg Hepatitis B surface antigen, ALT alanine
transaminase, Anti-HCV Hepatitis C antibody
Table 2 Tumour marker values for hcc cases and non-hcc
controls
Variables Mean ± Standard Deviation *p-value
HCC (n = 62) Non -HCC (n = 57)
AFP (IU/ml) 122.8 ± 148.2 11.2 ± 34.8 p < 0.001
DCP mAU/ml 1657.6 ± 687.1 59.1 ± 27.4 p < 0.001
*p-value < 0.05 is deemed significant
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From the ROC curve, the optimal cut-off level of AFP
was 18 IU/ml. The sensitivity and specificity of AFP in
differentiating HCC from benign liver diseases was 62.9
and 93.3 % respectively. The AUROC curve for AFP was
0.85 (95 % CI = 0.78 – 0.92). This was significantly lower
than the AUROC for DCP (p < 0.001).
Tumour marker values in relation to tumour profile,
disease aetiology and demographics
Table 3 shows the mean ± standard deviation of the
tumour markers in relation to the tumour sizes. As
could be seen from the table, none of the HCC patients
presented with tumour sizes less than 3 cm in diameter.
Both DCP and AFP values increased significantly with
increasing tumour sizes (p = 0.03).
Due again to late presentation, only three patients with
HCC had solitary-nodule tumours. The Mean ± Standard
Deviation (SD) DCP values were 1640 ± 700mAU/ml for
single-nodule tumours against 2000 ± 0 mAU/ml for
multiple-nodule tumours. No statistically significant cor-
relation was observed with reference to tumour nodular-
ity, probably due to the small number of single- nodule
tumours (p = 0.4). Extra-hepatic metastasis was noticed
in one patient and it was to the chest, presenting as
haemorrhagic pleural effusion. The DCP level was >2000
mAU/ml. Further statistical analysis may give misleading
results in view of the small number.
As shown in table 4, Hepatitis B virus aetiology was
significantly associated with high DCP levels (p < 0.001)
as well as high AFP values (p = 0.03).
The DCP levels were also stratified according to gen-
der. The males had significantly higher levels of DCP
than females, the Mean ± SD being1832 ± 496.5mAU/ml
against 1056 ± 906.8 mAU/ml respectively (p < 0.001).
Sensitivity and specificity of AFP and DCP
The sensitivity and specificity of AFP and DCP at differ-
ent cut-off points are presented in table 5. It could be
seen that as the sensitivity increases, so does the specifi-
city decrease and vice-versa.
Fig. 1 Box Plot for AFP values in both the HCC cases and Non-HCC controls. The Box indicates the 25th and 75th percentile of the data and the
middle line indicates the median. A line extends from the minimum to the maximum values excluding outliers that are displayed as separate points
Fig. 2 Box Plot for DCP in the HCC cases and non-HCC controls.
Outliers are smaller than the lowest quartile minus three times the
interquartile range or larger than the highest quartile plus 3 times
the interquartile range
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Correlation between serum AFP, DCP and other patient
characteristics
Univariate analysis was carried out using important con-
tinuous variables such as international normalised ratio,
Age, AST, ALT, Albumin and Total Bilirubin. The uni-
variate analysis identified AST as the only variable that
significantly correlated with the DCP values. (Spearman
rank correlation coefficient = 0.52 and p < 0.001).It is im-
portant to note also that AFP did not correlate with
DCP (Spearman rank correlation coefficient = 0.12 and
p = 0.36).
Discussion
Hepatocellular carcinoma is a disease with a poor
prognosis. Early detection could lead to improved
outcome through the application of potentially cur-
able interventions.
To achieve early diagnosis, attempts have been made
at discovering tumour markers. Alpha-fetoprotein and
Des-gamma-carboxyprothrombin are the most widely
used tumour markers but their usefulness in different
ethnic groups is still an issue of contention. In this study
we compared the usefulness of the two tumour markers
in the diagnosis of HCC among Nigerian patients.
Late presentation of HCC patients is commonly re-
ported in sub-Saharan Africa [2, 24–26]. This may ex-
plain why none of the HCC patients in this study had
tumour nodule sizes < 3 cm at presentation. As noted in
this study, the levels of AFP and DCP increased signifi-
cantly with increasing sizes of the tumour nodules. This
finding confirms several reports relating to tumour sizes
and AFP and DCP levels [14, 27–29] Durazo et al. [11]
in studying 73 patients with HCC noted that the mean
DCP value ranged from 7873 mAU/ml for tumour sizes <
3 cm to 12,403 mAU/ml for tumour size > 10 cm. Simi-
larly, the mean AFP values ranged from 599 ng/ml for
tumour sizes < 3 cm to 264, 016 for tumour sizes > 10 cm.
Nakamura et al. [17] while reporting on 1377 HCC cases
gave the median DCP values for tumour sizes < 3 cm, 3-
5 cm and > 5 cm as 30mAU/ml, 318 mAU/ml and 6000
mAU/ml respectively. The corresponding AFP values
were 25 ng/ml, 48 ng/ml and 556 ng/ml for tumour sizes
< 3 cm, 3–5 cm and >5 cm respectively. Non- delineation
of tumour sizes led to the discrepancies in earlier reports
on the sensitivity and specificity of AFP and DCP. The
controversy was largely laid to rest when it was discovered
that the sensitivity, specificity and accuracy of AFP and
DCP vary according to tumour sizes.
It would be safe to note that no definite inferences or
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Fig. 3 ROC Curves for DCP and AFP in the diagnosis of HCC. The area under the ROC curve (AUROC) for DCP in the diagnosis of HCC is 0.99
(95 % CI = 0.97 – 1.00) compared to the AUROC for AFP in the diagnosis of HCC 0.85 (95 % CI = 0.78 – 0.92), p < 0.001
Table 3 Values of DCP and AFP in relation to tumour sizes




HCC 62(100) 1657.4 ± 687.7 122.7 ± 148.3
Tumour Diameter
< 3 cm 0 0 0
3-5 cm 19(31) 1322.2 ± 858.7 94.9 ± 143.9
> 5 cm 43(69) 1805.5 ± 545.5 135.0 ± 150.2
Non-HCC 57(100) 59.1 ± 27.4 11.2 ± 34.8
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usefulness of Alpha-fetoprotein and Des-gamma- car-
boxyprothrombin in identifying asymptomatic patients
or patients on surveillance as none of the HCC patients
presented early (with tumour sizes < 3 cm). Strict sur-
veillance protocol is therefore imperative in the tropics.
From this study, it appears that DCP is more sensitive
and specific than AFP in differentiating hepatocellular
carcinoma from benign liver diseases among Nigerian
patients with tumour sizes ≥ 3 cm. DCP had a sensitivity
of 96.8 % and a specificity of 98.3 % at an ROC derived
cut-off value of 140 mAU/ml while AFP had a sensitivity
of 62.9%and a specificity of 93.3 % at an ROC derived
cut-off value of 18 IU/ml. This finding of higher sensitiv-
ity and specificity of DCP over AFP conforms to the
finding from many reports globally. DCP is known to be
more sensitive than AFP in the diagnosis of large size tu-
mours and advanced HCC [11, 15, 20, 29, 30] Sensitivity
of 96.8 % is similar to the finding by Wang et al., [18]
who reported a sensitivity of 100 % for tumours > 3 cm.
In the same vein, Nakamura et al., [17] gave a DCP sen-
sitivity of 95 % for tumour size >5 cm and 77 % for
tumour size 3-5 cm. These were higher than AFP sensi-
tivity of 78 % for tumour size > 5 cm and 68 % for
tumour size 3-5 cm at a cut-off point of 20 ng/ml. Still
in support of the finding in our study of higher sensitiv-
ity of DCP for tumour size ≥ 3 cm, Okuda et al., [29] re-
ported a DCP sensitivity of 81.5 % for tumours > 3 cm
and 28.6 % for tumour size < 2 cm. The corresponding
sensitivity for AFP was 70.4 % and 40 % respectively in-
dicating better sensitivity of AFP for small size tumours.
A large multi-centre study in America involving 419
HCC cases and 417 cirrhosis controls showed that for
Early Stage HCC, AFP had a better performance/accur-
acy than DCP but when intermediate- advanced stage
HCC (similar to most cases in our study) were com-
pared, then DCP had the better performance/accuracy
(AUROC = 0.89for DCP against 0.84 for AFP) [31].
The sensitivity of 96.8 % in our study is much higher
than 67.3 % reported in 1988 among South African
Black patients [13]. This may be due to the better sensi-
tivity and specificity of the enzyme-linked immunoassay
method currently in use, over the coagulase and other
similar methods used at that time [15, 16]. It may also
be due to the fact that the tumours were not delineated
according to their sizes.
In this study of 62 Nigerian patients with HCC, the
area under the curve (AUROC) of DCP was significantly
larger than that of AFP. This result indicates that DCP is
superior to AFP for the diagnosis of large tumours
(≥3 cm). Patients with high levels of DCP and low levels
of AFP were reported to have large tumours more than
3 cm compared with that of small tumours less than
2 cm, and a somewhat higher frequency of moderately
to poorly differentiated HCC compared with that of well
differentiated HCC [16, 30]. These results suggest that
DCP was closely related to large tumour diameter in
comparison to AFP and are in agreement with the re-
sults of the ROC analysis performed in our study. The
mechanism of this unique characteristic of DCP is not
well understood. However, it has been postulated that
the aggressive nature of DCP-positive HCC may be due
to the fact that DCP stimulates cell proliferation through
the Met-Janus Kinase signalling pathway, whereas for
vascular endothelial cells, it stimulates cell proliferation
and migration through the mitogen – activated protein
kinase signalling pathway [32].
Further, alpha-fetoprotein is shown in this study to be
less sensitive and of inferior accuracy in the diagnosis of
HCC when compared with DCP for patients presenting
with tumour size ≥3 cm. The sensitivity of 62.8 % is
lower than 83.7 % reported in 1988 in South Africa [13]
66 percent in 1974 in Uganda, [33] and 90 % in 1992 in
Zaire [34]. This may partly be due to the fact that some
of the studies were done using immuno - diffusion
method rather than radioimmunoassay and enzyme im-
munoassay. It has been found that with these latter (sen-
sitive) methods, a considerable proportion of patients
with HCC are not associated with a significant elevation
of AFP [35, 36]. This may explain why there is increasingly
less reliance on AFP as a diagnostic and surveillance tool
Table 4 Tumour marker values according to disease aetiology recorded as mean ± standard deviation
Disease Aetiology Number of patients (%) DCP(mAU/ml) AFP(IU/L)
HBV-related HCC 41(66.1 %) 1886.2 ± 410.6 149.0 ± 165.2
Non-HBV-related HCC 21(33.9 %) 1128.3 ± 893.0 59.8 ± 78.4
Table 5 DCP versus AFP in differentiation of patients with HCC
from those with benign liver diseases
DCP(mAU/ml) Sensitivity (%) Specificity (%)
> 40 100 26.7
> 100 98.4 91.7
> 140 96.8 98.3
> 200 93.6 100
AFP(IU/ml)
> 10 74.2 85.0
> 18 62.9 93.3
> 20 58.1 93.3
> 100 41.9 96.7
> 00 29.0 98.3
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in the management of HCC globally [22, 23, 35, 36]. A
study published in 1988 using 139 patients over a 4 year
period noted that the frequency of AFP negative or low-
level AFP hepatocellular carcinoma patients has been in-
creasing gradually [36]. A similar report using 606 patients
over a 9- year period arrived at the same conclusion [35].
A previous report from Nigeria gave a positive rate of
64 % at a cut-off level of 200 IU/ml. [37]. The sample size
of 14 HCC cases was however too small for any reliable
inference to be made from the study. On the other hand a
retrospective study from Enugu, Eastern Nigeria reviewed
the records of 150 HCC cases, and gave a positive rate of
44.5 %. The cut-off value was however not stated [24].
Lower AFP sensitivity than the figure in our study has
been reported in other parts of the world. At a cut-off
value of 20 ng/ml a low sensitivity of 63 % for all racial
groups and much lower sensitivity of 42.9 % for African
Americans has been reported [38] Brunello et al. [39] re-
ported a sensitivity of 43.5 % which is lower than the
finding in this study. A multi-centre large scale study in-
volving 1158 patients with HCC, noted a sensitivity of
54 % at a cut-off value of 20 ng/ml. [28]. This rate is also
lower than the finding in our study.
Notwithstanding its low sensitivity and accuracy AFP
is still the most widely used tumour marker for HCC
surveillance and diagnosis but there is the need for dis-
covery of better tumour markers. Univariate analysis in
this study showed no correlation between DCP and AFP
indicating that the combination of these markers is com-
plementary. DCP is not routinely employed for the diag-
nosis of HCC in Nigeria principally due to unavailability.
With the result of this study, a case may now be made
for its use as most cases of HCC seen in Nigeria are in
the late stages at presentation.
Hepatitis B viral aetiology was shown in this study to
be significantly associated with high DCP and AFP
values. A correlation has been found to exist between
HBsAg positivity and serum AFP levels in HCC patients.
HCC patients who are positive for HBsAg are signifi-
cantly more likely to be AFP positive and have higher
levels of AFP than those who are not, suggesting a rela-
tionship between HBV infection and AFP production
[27, 33, 40]. Similarly, DCP has also been reported to
perform better in those with viral aetiology [31].
Males were found to have significantly higher DCP
values than females in our study. This supports a similar
report in an earlier study and needs further investiga-
tions to explain the underlying mechanism [12].
Univariate analysis in this study showed that a correl-
ation exists between DCP and AST among HCC pa-
tients. This is in agreement with the report elsewhere
though their report also showed a correlation between
AST and AFP which was not seen in our study [9]. A
higher AST: ALT ratio has been shown in patients with
HCC- compared with those having benign liver diseases
likely due to an increase in cytosolic AST [35, 36, 41].
Conclusion
Our study showed that DCP is superior to AFP in differen-
tiating hepatocellular carcinoma from benign liver diseases
in Nigerian patients presenting with large-size tumours
(≥3 cm in diameter). A DCP value of >140mAu/ml is asso-
ciated with a high likelihood that the patient has HCC
(sensitivity/specificity ~97 %). Inferences on small size tu-
mours (<3 cm in diameter) could not be made as none of
the patients was diagnosed with HCC at an early stage.
Further studies using a larger sample size would be
needed to define the optimal cut-off point for DCP in
differentiating HCC from benign liver diseases among
Nigerians. Research into the role of DCP in the early
diagnosis of HCC at potentially curable stages, among
Nigerian patients would also be required.
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